Vector Targeting for Therapeutic Gene Delivery

David T. Curiel, M.D. heads the Gene Therapy Center of the University of Alabama at Birmingham. His scientific training includes tenure at the National Institutes of Health in Bethesda, Maryland and at the Pulmonary Branch of the National Heart, Lung, and Blood Institute from 1985-1989, as well as a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. Dr. Curiel has been at the University of Alabama at Birmingham since 1993 and is currently Director of the Gene Therapy Center as well as Director of the Division of Human Gene Therapy. He is also Jeanne and Anne Griffin Chair of Women's Cancer Research, and Professor of Experimental Gene Therapy at the Free University of Amsterdam. Joanne T. Douglas, Ph.D. is an Assistant Professor in the Division of Human Gene Therapy at the University of Alabama at Birmingham.

Preface. Contributors. PART I: TRANSDUCTIONALLY TARGETED VECTORS--NONVIRAL. Alternative Strategies for Targeted Delivery of Nucleic Acid-Liposome Complexes (N. Templeton). Targeted Gene Delivery via Lipidic Vectors (S. Li, et al.). Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment (K. Pirollo, et al.). Receptor-Directed Gene Delivery Using Molecular Conjugates (A. Ziady & P. Davis). PART II: TRANSDUCTIONALLY TARGETED VECTORS--VIRAL. Pseudotyping of Adenoviral Vectors (M. Havenga, et al.). Targeting of Adenoviral Gene Therapy Vectors: The Flexibility of Chemical and Molecular Conjugation (H. Haisma & M. Rots). Genetic Targeting of Adenoviral Vectors (T. Wickham). Strategies to Alter the Tropism of Adenoviral Vectors via Genetic Capsid Modification (D. Curiel). Conjugate-Based Targeting of Adeno-Associated Virus Vectors (S. Ponnazhagan, et al.). Receptor Targeting of Adeno-Associated Virus Vectors (H. Buning, et al.). Mechanisms of Retroviral Particle Maturation and Attachment (A. Miyanohara & T. Friedmann). Targeting Retroviral Vectors Using Molecular Bridges (J. Young). Genetic Targeting of Retroviral Vectors (D. Dingli & S. Russell). Genetic Engineering of Targeted Retroviral Vectors (E. Gordon, et al.). Targeting Measles Virus Entry (A. Hammond, et al.). Targeting of Poliovirus Replicons to Neurons in the Central Nervous System (C. Morrow, et al.). Generation of Safe, Targetable Sindbis Vectors that Have the Potential for Direct In Vivo Gene Therapy (D. Meruelo, et al.). Redirecting the Tropism of HSV-1 for Gene Therapy Applications (Q. Bai, et al.). Engineering Targeted Bacteriophage as Evolvable Vectors for Therapeutic Gene Delivery (D. Larocca & A. Baird). Targeting Bacteriophage Vectors (I. Saggio). PART III: TRANSCRIPTIONAL TARGETING. Tumor/Tissue Selective Promoters (M. Fernandez & N. Lemoine). Promoter Optimization and Artificial Promoters for Transcriptional Targeting in Gene Therapy (D. Nettelbeck, et al.). Physiological Targeting (K. Binley). Clostridium-Mediated Transfer of Therapeutic Proteins to Solid Tumors (P. Lambin, et al.). PART IV: TARGET DEFINITION. Selection of Peptides on Phage (M. Barry, et al.). Antibody Phage Display Libraries for Use in Therapeutic Gene Targeting (P. Rohrbach & S. Dubel). Single-Chain Fv Fragments from Phage Display Libraries (R. Kontermann). Retroviral Particle Display for Complex Glycosylated and Disulfide-Bonded Protein Domains (S. Kayman). Cell Surface Display and Cytometric Screening for Protein Ligand Isolation and Engineering (P. Daugherty). PART V: MONITORING OF TARGETING. Monitoring Gene Therapy By Positron Emission Tomography (H. Herschman, et al.). Index.